OBJECTIVE: There is limited evidence on the economic implications of assessing patients' access to personalised treatments through Comprehensive Genomic Profiling (CGP) and Molecular Tumour Board (MTB), prompting the need to analyse their impact on the cost of the cancer diagnostic journey (from hospital admission to MTB evaluation) and accessibility to personalised therapies. DESIGN: Retrospective observational cohort. SETTING: Patients discussed from April 2020 to September 2021 by the institutional MTB operating at Fondazione IRCCS Istituto Nazionale Tumori of Milan, an Italian centre of excellence in oncology pertaining to the national health system. PARTICIPANTS: 676 patients focused on: non-small cell lung cancer (NSCLC), cholangiocarcinoma (CCA), pancreatic carcinoma (PC) and gastro-oesophageal carcinoma (GEC). We defined two different scenarios: (1) patients tested with small Next-Generation Sequencing (NGS) panels (≤60 biomarkers) vs (2) patients tested with comprehensive panels (>
60 biomarkers). MAIN OUTCOMES AND MEASURES: We measured (1) patients' eligibility to personalised therapies based on genomic data obtained using targeted somatic NGS panels, (2) MTB cost and the overall diagnostic journey cost and (3) the cost to find a patient eligible to access personalised treatments. RESULTS: Tumour profiling with comprehensive NGS panels improved patients' eligibility to personalised therapies compared with small panels (NSCLC: 39% comprehensive panel vs 37% small panel
CCA: 43% vs 17%
PC: 35% vs 3%
GEC: 40% vs 0%). The overall diagnostic journey cost per patient was between 3.2K and 7.4K (NSCLC: 7.4K comprehensive panel vs 6.4K small panel
CCA: 4.9K vs 3.7K
PC: 5.8K vs 4.5K
GEC: 4.2K vs 3.2K). MTB discussion accounted for only 2-3% of the diagnostic journey cost per patient (around 113€/patient). The cost to find patient eligible for personalised treatments varied significantly according to panel size and tumour setting (NSCLC: 5K comprehensive panel vs 2.8K small panel
CCA: 4.4K vs 4.4K
PC: 5.5K vs 27K
GEC: 5.2K vs not measurable since none of the patients analysed with small NGS panels were eligible). CONCLUSIONS AND RELEVANCE: MTB discussion of genomic data obtained with NGS comprehensive panels significantly increases patient eligibility to targeted therapies and optimise the cost to find a patient eligible to personalised treatments, mainly for CCA, PC and GEC patients.